









Markets
/
Stocks
/
nasdaq-iccm
/

Icecure Medical Ltd

ICCM

1.050USD

+0.010+0.96%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

61.63MMarket Cap

LossP/E TTM



Icecure Medical Ltd

1.050

+0.010+0.96%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a very weak stock market performance, the company shows strong technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

110 / 207

Overall Ranking

248 / 4720

Industry

Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 3 analysts

Buy

Current Rating

2.590

Target Price

+149.04%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Icecure Medical Ltd is an Israel-based company that is engaged in the healthcare sector. The Company operates as commercial stage medical device company focusing on the research, development and marketing of cryoablation systems, disposables and technologies based on liquid nitrogen, or LN2, for treating tumors. Cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in breast, lungs, kidneys, bones and other indications. Company's lead product is ProSense system, a single probe system, but in addition the Company developed an additional multi probe system that is expected to have the ability to freeze several tumors simultaneously or larger tumors, named MultiSense system, which has not yet been commercialized.

Growing

The company is in a growing phase, with the latest annual income totaling USD 3.29M.

Fairly Valued

The company’s latest PE is -3.74, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 28.04M shares, increasing 0.20% quarter-over-quarter.

Held by Ken Fisher

Star Investor Ken Fisher holds 0.00 shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.36.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 5.61, which is lower than the Healthcare Equipment & Supplies industry's average of 7.32. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 525.00K, representing a year-over-year decrease of 48.07%, while its net profit experienced a year-over-year decrease of 9.19%.

Score

Industry at a Glance

Previous score

5.61

Change



Financials

6.78

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.38

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.77

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

4.03

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.09

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Healthcare Equipment & Supplies industry's average of 3.59. Its current P/E ratio is -3.70, which is -2.80% below the recent high of -3.60 and -11.20% above the recent low of -4.12.

Score

Industry at a Glance

Previous score

2.80

Change

1.2

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 110/207

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 8.00, which is higher than the Healthcare Equipment & Supplies industry's average of 7.70. The average price target for Icecure Medical Ltd is 2.77, with a high of 3.00 and a low of 2.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 3 analysts

Buy

Current Rating

2.590

Target Price

+146.67%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

Total

Median

Average

Company name

Ratings

Analysts

Icecure Medical Ltd

ICCM

Boston Scientific Corp

BSX

Edwards Lifesciences Corp

Intuitive Surgical Inc

ISRG

Veeva Systems Inc

VEEV

Thermo Fisher Scientific Inc

TMO

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 7.17, which is higher than the Healthcare Equipment & Supplies industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 1.28 and the support level at 0.82, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.17

Change

0.01

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(5)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.002

Neutral

RSI(14)

54.893

Neutral

STOCH(KDJ)(9,3,3)

46.777

Buy

ATR(14)

0.054

Low Volatility

CCI(14)

2.880

Neutral

Williams %R

48.148

Neutral

TRIX(12,20)

0.396

Sell

StochRSI(14)

45.953

Neutral

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

1.042

Buy

MA10

1.027

Buy

MA20

1.033

Buy

MA50

0.981

Buy

MA100

1.009

Buy

MA200

1.110

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-19

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Haixiang (Li)

25.85M

Shamir (Eyal)

590.31K

+13.38%

Tsimerman (Ronen)

355.08K

+15.46%

Mayron (Ron)

278.02K

+24.91%

Tel-Tzure (Tlalit Bussi)

191.81K

+22.57%

Levav (Shay)

141.86K

+36.18%

Muchnik (Naum)

140.42K

+33.36%

Huang (Yang)

113.44K

+54.72%

Dotan (Merav Nir)

88.94K

+53.09%

Malik (Galit)

79.67K

+41.40%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.36, which is lower than the Healthcare Equipment & Supplies industry's average of 3.87. The company's beta value is 2.50. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.